Development of a Sustained-Release Biodegradable Polymer Delivery System for Site-Specific Delivery of Oligonucleotides: Characterization of P(LA-GA) Copolymer Microspheres In Vitro

References

• Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution and stability of oligodeoxynucleotides phosphorothioates in mice. Proc. Natl. Acad. Sci.(USA) 1992; 88: 7595–7599
   Web of Science ®Google Scholar
• Akhtar S., Juliano R. L. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 1992; 2: 139–144
   PubMedGoogle Scholar
• Akhtar S. Delivery Strategies for Antisense Oligonucleotide Therapeutics. CRC Press, Boca RatonUSA 1995
   Google Scholar
• Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol 1997; 18: 12–18
   PubMed Web of Science ®Google Scholar
• Akhtar S., Rossi J. J. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?. J. Antimicrob. Chemotherapy 1996; 38: 159–165
   PubMed Web of Science ®Google Scholar
• Akhtar S., Kole R., Juliano R. L. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 1991; 49: 1793–1801
   PubMed Web of Science ®Google Scholar
• Akhtar S., Lewis K. J. Antisense oligodeoxynucleotide delivery to cultured macrophages is improved by incorporation into sustained release biodegradable polymer microspheres. Int. J. Pharm. 1997; 151: 57–67
   Web of Science ®Google Scholar
• Alonso M. J., Cohen S., Park T. G., Gupta R. K., Siber G. R., Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm. Res. 1993; 10: 945–953
   PubMed Web of Science ®Google Scholar
• Bhardwaj S. B., Shukla A. J., Collins C. C. Effect of varying drug loading on particle size distribution and drug release kinetics of verapamil hydrochloride microspheres prepared with cellulose esters. J. Microencapsulation 1995; 12: 71–81
   PubMed Web of Science ®Google Scholar
• Brem H. Polymers to treat brain tumours. Biomaterials 1990; 11: 699–701
   PubMed Web of Science ®Google Scholar
• Bolton E. T., McCarthy B. J. A general method for the isolation of RNA complementary to DNA. Proc. Natl. Acad. Sci.(USA) 1962; 48: 1390–1397
   PubMed Web of Science ®Google Scholar
• Chavany C., Le Doan T., Couvreur P., Puisieux F., Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric particles for antisense oligonucleotides. Pharm. Res. 1992; 9: 441–449
   PubMed Web of Science ®Google Scholar
• Chavany C., Saison-Behmoaras T., Le Doan T., Puisieux F., Couvreur P., Hélène C. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 1994; 11: 1370–1378
   PubMed Web of Science ®Google Scholar
• Chu C. C. The in-vitro degradation of poly(glycolic acid) sutures-effect of pH. J. Biomed. Mater. Res. 1981; 15: 795–804
   PubMed Web of Science ®Google Scholar
• Chu C. C. The effect of pH on die in vitro degradation of poly(glycolide lactide) copolymer absorbable sutures. J. Biomed. Mater. Res. 1982; 16: 117–124
   PubMed Web of Science ®Google Scholar
• Cohen I., Yoshioka T., Lucarelli M., Hwang L. H., Langer R. Controlled delivery systems for proteins based on polydactic/glycolic acid) microspheres. Pharm. Res. 1991; 8: 713–720
   PubMed Web of Science ®Google Scholar
• Cortesi R., Esposito E., Menegatti E., Gambari R., Nastruzzi C. Gelatin microspheres as a new approach for the controlled delivery of synthetic oligonucleotides and PCR-generated DNA fragments. Int. J. Pharm. 1994; 105: 181–186
   Web of Science ®Google Scholar
• Coulson J. M., Poyner D. R., Chantry A., Irwin W. J., Akhtar S. A non-antisense sequence-selective effect of a phosphorothioate oligonucleotide targeted to EGFR in A431 cells. Mol. Pharmacol. 1996; 50(2)314–325
   PubMed Web of Science ®Google Scholar
• Dagle J. M., Andracki M. E., DeVine R. J., Walder J. A. Physical properties of oligonucleotides containing phos-phoramidate-modified internucleoside linkages. Nucl. Acids Res. 1991; 19: 1805–1810
   PubMed Web of Science ®Google Scholar
• Davis S. S., Illum L., Moghimi S. M., Davies M. C., Porter C. J. H., Muir I. S., Brindley A., Christy N. M., Norman M. E., Williams P., Dunn S. E. Microspheres for targeting drugs to specific body sites. J. Controlled Rel. 1993; 24: 157–163
   Web of Science ®Google Scholar
• Fournier C., Hecquet B., Bouffard P., Vert M., Caty A., Vilian M-O., Vanseymortier L., Merle S., Krikorian A., Lefebvre J., Delobelle A., Adenis L. Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumours. Can. Res. 1991; 51: 5384–5391
   PubMed Web of Science ®Google Scholar
• Hoke G. D., Draper K., Freier S. M., Gonzalez C., Driver V. B., Zounes M. C., Ecker D. J. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridisation and antiviral efficacy versus herpes simplex virus infection. Nucl. Acids Res. 1991; 19: 5743–5748
   PubMed Web of Science ®Google Scholar
• Hudson A. J., Lewis K. J., Rao V. M., Akhtar S. Biodegradable polymer matrices for the sustained exogenous delivery of a biologically active c-myc hammerhead ribozyme. Int. J. Pharm. 1996a; 136: 23–29
   Web of Science ®Google Scholar
• Illum L., Davis S. S., Muller R. H., Mak E., West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block-copolymer - Poloxamine 908. Life Sci. 1987; 40: 367–374
   PubMed Web of Science ®Google Scholar
• Itakura K., Rossi J. J., Wallace R. B. Synthesis and use of synthetic oligonucleotides. Ann. Rev. Biochem. 1984; 53: 323–356
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Akhtar S. Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res. Develop. 1992; 2: 165–176
   PubMedGoogle Scholar
• Kamei K., Linuma Y., Yuasa Y., Saikawa A., Igari Y., Ogawa Y. LHRH agonist depot formulations. Comparative studies of Decapeptyl with Enantone. Europ. Hosp. Pharm. 1995; 1: 113–120
   Google Scholar
• Le Corre P., Le Guevello P., Gajan V., Chavanne F., Le Verge R. Preparation and characterisation of bupivacaine-loaded polylactide and polylactide-co-glycolide microspheres. Int. J. Pharm. 1994; 107: 41–49
   Web of Science ®Google Scholar
• Lewis K. J., Irwin W. J., Akhtar S. Biodegradable poly(L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. J Controlled Release 1995; 37: 173–183
   Web of Science ®Google Scholar
• Maher L. J., Dolnick B. J. Comparative hybrid arrest by tandem antisense oligodeoxyribonucleotides or oligodeoxyribonucleotide methylphosphonates in a c11-free sysytem. Nucl. Acids Res. 1988; 16: 3341–3358
   PubMed Web of Science ®Google Scholar
• Nakada Y., Fattal E., Foulquier M., Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanopartcles after intravenous administration in mice. Pharm Res. 1996; 13: 38–43
   PubMed Web of Science ®Google Scholar
• Narayani R., Rao K. P. Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres. J. Microencapsulation 1994; 11: 69–77
   PubMed Web of Science ®Google Scholar
• Ogawa Y., Okada H., Yamamoto M., Shimamoto T. In viv o release profile of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers. Chem. Pharm. Bull. 1988b; 36: 2576–2581
   PubMed Web of Science ®Google Scholar
• Ogawa Y., Yamamoto M., Okada H., Yashiki T., Shimamoto T. A new technique to efficiently entrap leuprolide acetate into micropsheres of copoly(lactic/glycolic acid). Chem. Pharm. Bull. 1988a; 36: 1095–1103
   PubMed Web of Science ®Google Scholar
• Ropert C., Okruszek P., Couvreur P., Malvy C. Retroviral inhibition by antisense oligonucleotides determined by intracellular stability. Antisense Res. Develop. 1994; 4: 207–210
   PubMedGoogle Scholar
• Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual second edition. Cold Spring Harbour Laboratory Press. 1989
   Google Scholar
• Schwab C., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., Saison-Behmoaras T. Antisense oligonucleotides adsorbed onto polycyanoacrylate nanoparticles specifically inhibit mutated Ha-ras mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci (USA) 1994; 91: 10460–10464
   PubMed Web of Science ®Google Scholar
• Stein C. A., Mori K., Loke S. L., Subasinghe C., Shinozuka K., Cohen J. S., Neckers L. M. Phosphorothioate and normal oligodeoxyribonucleotides with 5'-linked acridine: characterization and preliminary kinetics of cellular uptake. Gene 1988; 72: 333–341
   PubMed Web of Science ®Google Scholar
• Tsai D. C., Howard S. A., Hogan T. F., Malanga C. J., Kandzari S. J., Ma J. K. H. Preparation of in vitro evaluation of polylactic acid- mitomycin C microcapsules. J. Microencapsulation 1986; 3: 181–193
   PubMedGoogle Scholar
• Visscher G. E., Pearson J. E., Fong J. W., Argentieri Robinson R. L., Maulding H. V. Effect of particle size on the in vitro and in vivo degradation rates of poly(D,L-lactide-coglycolide) microcapsules. J. Biomed. Mater. Res. 1988; 22: 733–746
   PubMed Web of Science ®Google Scholar
• Wang H. T., Palmer H., Linhardt R. J., Flanagan D. R., Schmitt E. Degradation of poly(ester) microspheres. Biomaterials 1990; 11: 679–685
   PubMed Web of Science ®Google Scholar
• Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 1986; 13: 97–102
   PubMedGoogle Scholar
• Zhao Q., Temsamani J., Agrawal S. Use of cyclodextrin and its derivatives for oligonucleotide delivery. Antisense Res. Develop. 1995; 5: 185–192
   PubMedGoogle Scholar